Cogent Biosciences, Inc. Stock-Based Compensation
Cogent Biosciences, Inc. (COGT) reported Stock-Based Compensation of $34.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-10
- Cogent Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $17.11M, a 76.07% increase year-over-year.
- Cogent Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $16.91M, a 68.94% increase year-over-year.
- Cogent Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $15.75M, a 57.87% increase year-over-year.
- Cogent Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $10.60M, a 2.37% increase year-over-year.
- Cogent Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $46.08M, a 15.95% increase from fiscal 2024.
- Cogent Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $39.74M, a 29.78% increase from fiscal 2023.
- Cogent Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $30.62M, a 66.71% increase from fiscal 2022.
- Cogent Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $18.37M, a 57.18% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $34.02M 10-Q · filed 2026-08-10 | $49.77M derived: sum of 3 quarters · filed 2026-08-10 | $60.37M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $16.91M 10-Q · filed 2026-05-05 | $32.66M derived: sum of 2 quarters · filed 2026-05-05 | $43.26M derived: sum of 3 quarters · filed 2026-05-05 | $52.98M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $15.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $26.36M derived: sum of 2 quarters · filed 2026-02-17 | $36.07M derived: sum of 3 quarters · filed 2026-08-10 | $46.08M 10-K · filed 2026-02-17 |
| 2025-09-30 | $10.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $20.32M derived: sum of 2 quarters · filed 2026-08-10 | $30.33M 10-Q · filed 2025-11-07 | $40.30M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $9.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $19.72M 10-Q · filed 2026-08-10 | $29.70M derived: sum of 3 quarters · filed 2026-08-10 | $40.06M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $10.01M 10-Q · filed 2026-05-05 | $19.98M derived: sum of 2 quarters · filed 2026-05-05 | $30.34M derived: sum of 3 quarters · filed 2026-05-05 | $40.35M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $9.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $20.34M derived: sum of 2 quarters · filed 2026-02-17 | $30.35M derived: sum of 3 quarters · filed 2026-02-17 | $39.74M 10-K · filed 2026-02-17 |
| 2024-09-30 | $10.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $20.37M derived: sum of 2 quarters · filed 2025-11-07 | $29.76M 10-Q · filed 2025-11-07 | $38.61M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $10.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $19.41M 10-Q · filed 2025-08-05 | $28.26M derived: sum of 3 quarters · filed 2026-02-17 | $37.01M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $9.39M 10-Q · filed 2025-05-06 | $18.24M derived: sum of 2 quarters · filed 2026-02-17 | $27.00M derived: sum of 3 quarters · filed 2026-02-17 | $34.16M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $8.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $17.61M derived: sum of 2 quarters · filed 2026-02-17 | $24.77M derived: sum of 3 quarters · filed 2026-02-17 | $30.62M 10-K · filed 2026-02-17 |
| 2023-09-30 | $8.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $15.92M derived: sum of 2 quarters · filed 2024-11-12 | $21.77M 10-Q · filed 2024-11-12 | $26.81M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $7.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $13.01M 10-Q · filed 2024-08-06 | $18.05M derived: sum of 3 quarters · filed 2025-02-25 | $22.67M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $5.85M 10-Q · filed 2024-05-07 | $10.89M derived: sum of 2 quarters · filed 2025-02-25 | $15.51M derived: sum of 3 quarters · filed 2025-02-25 | $20.04M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $5.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $9.66M derived: sum of 2 quarters · filed 2025-02-25 | $14.19M derived: sum of 3 quarters · filed 2025-02-25 | $18.37M 10-K · filed 2025-02-25 |
| 2022-09-30 | $4.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $9.16M derived: sum of 2 quarters · filed 2023-11-07 | $13.33M 10-Q · filed 2023-11-07 | $17.18M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $4.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $8.71M 10-Q · filed 2023-08-08 | $12.56M derived: sum of 3 quarters · filed 2024-02-26 | $16.02M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $4.17M 10-Q · filed 2023-05-09 | $8.03M derived: sum of 2 quarters · filed 2024-02-26 | $11.49M derived: sum of 3 quarters · filed 2024-02-26 | $14.08M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $7.32M derived: sum of 2 quarters · filed 2024-02-26 | $9.90M derived: sum of 3 quarters · filed 2024-02-26 | $11.69M 10-K · filed 2024-02-26 |
| 2021-09-30 | $3.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $6.05M derived: sum of 2 quarters · filed 2022-11-14 | $7.83M 10-Q · filed 2022-11-14 | $8.70M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $2.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $4.37M 10-Q · filed 2022-08-09 | $5.24M derived: sum of 3 quarters · filed 2022-08-09 | $8.75M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.78M 10-Q · filed 2022-05-10 | $2.65M derived: sum of 2 quarters · filed 2022-05-10 | $6.16M derived: sum of 3 quarters · filed 2022-05-10 | $7.03M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $866.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $4.38M derived: sum of 2 quarters · filed 2022-03-15 | $5.25M derived: sum of 3 quarters · filed 2022-03-15 | $6.02M 10-K · filed 2022-03-15 |
| 2020-09-30 | $3.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $4.38M derived: sum of 2 quarters · filed 2021-11-10 | $5.15M 10-Q · filed 2021-11-10 | $5.99M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $870.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $1.64M 10-Q · filed 2021-08-16 | $2.48M derived: sum of 3 quarters · filed 2021-08-16 | $3.27M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $769.00K 10-Q · filed 2021-05-12 | $1.61M derived: sum of 2 quarters · filed 2021-05-12 | $2.40M derived: sum of 3 quarters · filed 2021-05-12 | $3.28M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $842.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $1.63M derived: sum of 2 quarters · filed 2021-03-16 | $2.52M derived: sum of 3 quarters · filed 2021-03-16 | $3.24M 10-K · filed 2021-03-16 |
| 2019-09-30 | $788.00K 10-Q · filed 2019-11-12 | $1.67M derived: sum of 2 quarters · filed 2019-11-12 | $2.40M 10-Q · filed 2020-11-09 | $3.30M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-06-30 | $885.00K 10-Q · filed 2019-11-12 | $1.61M 10-Q · filed 2020-08-11 | $2.51M derived: sum of 3 quarters · filed 2020-05-11 | $3.37M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-03-31 | $726.00K 10-Q · filed 2020-05-11 | $1.63M derived: sum of 2 quarters · filed 2020-05-11 | $2.49M derived: sum of 3 quarters · filed 2020-05-11 | $3.33M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $902.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $1.76M derived: sum of 2 quarters · filed 2020-03-26 | $2.61M derived: sum of 3 quarters · filed 2020-03-26 | $3.09M 10-K · filed 2020-03-26 |
| 2018-09-30 | $860.00K 10-Q · filed 2019-11-12 | $1.71M derived: sum of 2 quarters · filed 2019-11-12 | $2.19M 10-Q · filed 2019-11-12 | $2.65M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $847.00K 10-Q · filed 2019-11-12 | $1.33M 10-Q · filed 2019-08-12 | $1.79M derived: sum of 3 quarters · filed 2019-11-12 | $2.08M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-03-31 | $479.00K 10-Q · filed 2019-11-12 | $939.00K derived: sum of 2 quarters · filed 2019-11-12 | $1.24M derived: sum of 3 quarters · filed 2019-11-12 | $1.52M derived: sum of 4 quarters · filed 2019-11-12 |
| 2017-12-31 | $460.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | $759.00K derived: sum of 2 quarters · filed 2019-03-28 | $1.04M derived: sum of 3 quarters · filed 2019-03-28 | $1.34M 10-K · filed 2019-03-28 |
| 2017-09-30 | $299.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $581.00K derived: sum of 2 quarters · filed 2018-11-13 | $881.00K 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $282.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $582.00K 10-Q · filed 2018-08-13 | ||
| 2017-03-31 | $300.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |